Phase 2 Glioma Clinical Trials
89 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 89 trials
Recruiting
Phase 1Phase 2
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
Brain CancerGBMGlioma+12 more
National Institute of Neurological Disorders and Stroke (NINDS)40 enrolled1 locationNCT07416188
Recruiting
Phase 2
Methimazole in Patients With Progressive Glioblastoma
GlioblastomaGlioma
Case Comprehensive Cancer Center19 enrolled1 locationNCT05607407
Recruiting
Phase 1Phase 2
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
Malignant Glioma
National Cancer Institute (NCI)132 enrolled127 locationsNCT05099003
Recruiting
Phase 1Phase 2
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
OsteosarcomaEwing SarcomaNeuroblastoma+4 more
Milton S. Hershey Medical Center289 enrolled11 locationsNCT06465199
Recruiting
Phase 2
Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment
Recurrent GliomaRecurrent WHO Grade 2 GliomaRecurrent WHO Grade 3 Glioma+1 more
National Cancer Institute (NCI)30 enrolled27 locationsNCT05859334
Recruiting
Phase 1Phase 2
PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma
MedulloblastomaEpendymomaDiffuse Midline Glioma+1 more
Washington University School of Medicine68 enrolled3 locationsNCT06639607
Recruiting
Phase 2
Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas
BRAF V600 MutationLow-grade GliomaLow Grade Glioma of Brain+1 more
University of California, San Francisco96 enrolled7 locationsNCT07110246
Recruiting
Phase 2
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Central Nervous System DiseasesBrain CancerGlioblastoma Multiforme (GBM)+4 more
Black Diamond Therapeutics, Inc.162 enrolled13 locationsNCT07326566
Recruiting
Phase 1Phase 2
Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma
Glioblastoma (GBM)Recurrent GlioblastomaNewly Diagnosed Glioblastoma+1 more
Trogenix ltd68 enrolled2 locationsNCT07346144
Recruiting
Phase 2
Study of Olutasidenib and Temozolomide in HGG
Metastatic Brain TumorIDH1 MutationAstrocytoma, Grade IV+16 more
Rigel Pharmaceuticals60 enrolled20 locationsNCT06161974
Recruiting
Phase 2
Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma
Advanced Pheochromocytoma and ParagangliomaPCPG
Jazz Pharmaceuticals90 enrolled9 locationsNCT07282587
Recruiting
Phase 1Phase 2
Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK
Pediatric Low-grade Glioma
St. Justine's Hospital50 enrolled8 locationsNCT06666348
Recruiting
Phase 2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Pancreatic Neuroendocrine TumorVon Hippel-Lindau DiseasePheochromocytoma/Paraganglioma+2 more
Merck Sharp & Dohme LLC355 enrolled84 locationsNCT04924075
Recruiting
Phase 1Phase 2
Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
GliomaGlioblastoma Multiforme
Aveta Biomics, Inc.30 enrolled2 locationsNCT06011109
Recruiting
Phase 1Phase 2
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
ParagangliomaPheochromocytomaSolid Tumor Cancer+19 more
Fundación de investigación HM25 enrolled1 locationNCT06607692
Recruiting
Phase 1Phase 2
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
CancerBrain TumorBrain Cancer+6 more
Northwell Health67 enrolled1 locationNCT03213002
Recruiting
Phase 2
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Metastatic Brain TumorGlioblastomaGlioblastoma Multiforme+7 more
Nationwide Children's Hospital120 enrolled20 locationsNCT05843253
Recruiting
Phase 2
DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
High Grade GliomaAnaplastic Astrocytoma
Ashish Shah33 enrolled1 locationNCT06264388
Recruiting
Phase 1Phase 2
Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors
GliomaCNS Tumor, AdultCNS Tumor, Childhood
Centre Leon Berard70 enrolled12 locationsNCT07243470
Recruiting
Phase 2
Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors
RecurrenceRefractoryHigh Grade Glioma+4 more
Clinica Universidad de Navarra, Universidad de Navarra39 enrolled2 locationsNCT07424092